<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133496</url>
  </required_header>
  <id_info>
    <org_study_id>095-06</org_study_id>
    <nct_id>NCT01133496</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-way, Single-dose, Crossover Bioequivalence Study of Alendronate Sodium 70 mg Tablets of Dr Reddy's, India and Fosamax® Tablets of Merck &amp; Co., Inc., USA, in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bioequivalence of Alendronate Sodium 70 mg of
      Dr. Reddy's and Fosamax Tablets 70 mg of Merck &amp; Co.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,
      crossover oral bioequivalence study of Alendronate sodium 70 mg tablets of Dr Reddy's
      Laboratories Limited, India and Fosamax® tablets of Merck &amp; Co., Inc., USA, in healthy,
      adult, human subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Alendronate Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alendronate Sodium Tablets, 70 mg of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosamax Tablets 70 mg of Merck &amp; Company. Inc., USA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate Sodium Tablets, 70 mg</intervention_name>
    <description>Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.</description>
    <arm_group_label>Alendronate Sodium</arm_group_label>
    <arm_group_label>Fosamax</arm_group_label>
    <other_name>Fosamax Tablets 70 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy human subjects aged between 18 and 45 years (including both).

          2. Subjects with a BMI between 18.5 - 24.9 Kg/m2 but weight not less than 45 Kgs.

          3. Female subjects who are postmenopausal or surgically sterile.

          4. Female subjects of child bearing potential practicing an acceptable method of birth
             control for the duration of the study as judged by the investigator(s), such as
             condoms, foams, jellies, diaphragm, intrauterine device (IUD) or abstinence.

          5. Subjects with normal health as determined by personal medical history, clinical
             examination, and laboratory examinations and serology tests.

          6. Subjects having normal 12-lead electrocardiogram (ECG).

          7. Subjects having normal chest X-Ray (P/A view).

          8. Subjects able to communicate effectively.

          9. Subjects willing to given written informed consent and adhere to all the requirements
             of this protocol.

        Exclusion Criteria:

          1. Subjects having contraindications or hypersensitivity to Alendronate sodium or related
             drugs.

          2. History or presence of any medical condition or disease according the opinion of the
             physician.

          3. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          4. History or presence of significant alcoholism or drug abuse in the past one year.

          5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day or
             consumption of tobacco products).

          6. Difficulty with donating blood.

          7. Difficulty in swallowing solids like tablets or capsules.

          8. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.

          9. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.

         10. Pulse rate less than 50/minute or more than 100/minute.

         11. Use of any prescribed medication during last two weeks or OTC medical products during
             the last one week preceding the first dosing.

         12. Major illness during 3 months before screening.

         13. Participation in a drug research study within past 3 months.

         14. Donation of blood in the past 3 months before screening.

         15. Female volunteers demonstrating a positive pregnancy screen.

         16. Female volunteers who are currently breast-feeding.

         17. Female volunteers with child bearing potential using prohibited contraceptive method
             (Oral, Injectable or Implantable hormonal agents).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Naba Kr Talukdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GVK Biosciences Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GVK Biosciences Pvt. Ltd.,</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan/Senior Director - R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Alendronate Sodium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

